Noveome Biotherapeutics

Noveome Biotherapeutics is a private, clinical-stage company developing ST266, a proprietary secretome-derived biologic. Its platform leverages a complex mixture of hundreds of proteins and factors designed to mimic and stimulate the body's natural healing processes across multiple pathways. The pipeline includes programs in necrotizing enterocolitis (NEC) in premature infants and various ophthalmic indications, with early clinical trials demonstrating promising tolerability and biologic activity. Led by a team with deep pharmaceutical experience, particularly from Allergan, Noveome is positioning its multi-targeted approach as a potential solution for complex, inflammatory, and tissue-damaging diseases with high unmet need.

ST266, a first-of-its-kind, multi-targeted secretome containing hundreds of biologically active proteins, growth factors, and cytokines that modulate inflammation, promote neuroprotection, and stimulate tissue healing.

Noveome faces competition from both single-target biologics and other regenerative medicine approaches (e.g., stem cells, exosomes) in each therapeutic area. Its differentiation lies in ST266's defined, cell-free composition of hundreds of factors, aiming for a more potent and coordinated healing response than single agents, while avoiding the logistical and safety complexities of live cell therapies.